Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...

ARCTURUS THERAPEUTICS ($ARCT) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.52 per share, beating estimates of -$1.36 by ...

The market expects Arcturus Therapeutics (ARCT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Good day. I would ...

Once you locate the Big Dipper in the sky, it can be used to find the stars Arcturus and Spica. Credit: Creators.com illustration OK, I admit I may not remember where my car is parked, but I sure ...

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...